Encouraging the research and manufacturing of both new drugs and generic drugs fits the current situation in China's medicine industry, which on one hand protects IPR development and on the other hand improves the healthcare services for the people, said the official.
From 2011 to 2017, altogether 323 "innovative" drugs were approved for clinical research in China, and 139 new generic drugs entered the market.
【国内英语资讯:China encourages generic drug production amid increased regulation】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15